QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 revelation-biosciences-q2-2024-gaap-eps-513

Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(5.13) per share.

 watching-revelation-biosciences-zacks-small-cap-research-gives-stock-1240-price-valuation

https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_07082024_REVB_Sorensen.pdf

 why-is-nano-cap-revelation-biosciences-stock-skyrocketing-on-monday

Revelation Biosciences reveals positive safety and biomarker data from its Phase 1 study (RVL-HV02) of Gemini. The study met it...

 revelation-biosciences-announces-phase-1-results-for-gemini-demonstrates-safety-tolerability-and-dose-dependent-biomarker-changes-enables-further-development-across-multiple-indications

-Gemini administration induced statistically significant, dose dependent changes in key biomarkers of activity--Gemini was safe...

 revelation-biosciences-q1-eps-246-misses-177-estimate

Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(2.46) per share which missed the analyst consensus estimate...

 revelation-biosciences-q4-eps-833-beats-1377-estimate

Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(8.33) per share which beat the analyst consensus estimate o...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION